Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Search Site

Over 2,750 Pages of
Hepatitis C Info, Here:
Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Hepatitis B, Chronic: Entecavir (NICE)
You must be a registered user to access the content and receive email bulletins from Healthcare Republic. If you have a paid subscription to MIMS or MIMS for Nurses, please activate your subscription. Otherwise, complete the free registration by choosing

Genelabs, NHRI collaborate on hepatitis C drug candidates
REDWOOD CITY, Calif.- has entered into a collaborative research agreement with the to discover and develop compounds that target the hepatitis C virus (HCV). HCV drug candidates will be developed using Genelabs' lead compounds on an existing target the

UPDATES AND COMMENTARY RSS Feed

Hep C Treatment: Comparing the Pegylated Interferons
Learn about the facts on pegylated interferon alfa-2a and pegylated interferon alfa-2b, the standard treatment for chronic Hepatitis C. Comparing and contrasting the pegylated interferons may help better explain a physician’s preference or indifference between the two when treating their...

Vertex's Advanced Trial Could Change HCV Treatment
Hundreds of non-responders to interferon-ribavirin combination therapy will be enrolled in a late stage clinical trial for Vertex's telaprevir....

Silymarin Improves Quality of Life During Hepatitis C Treatment
Although a large-scale study concluded long-term interferon therapy to be ineffectual for Hepatitis C management, it demonstrated improvements in quality of life for participants supplementing with silymarin....

Determinants of Outcome of Compensated Hepatitis C Virus-Related Cirrhosis

table  1.   Baseline Characteristics of Interferon-Treated Patients and Untreated Patients
Treated Patients (n = 59) Untreated Patients (n = 44)
Age at diagnosis (y)* 55 ± 9 56 ± 14
Sex (M/F) 39/20 33/11
Transfusion (%) 63 55
IVDU (%)  8 18
Duration of HCV infectiondagger (yr)* 16 ± 9 18 ± 10
Hepatomegaly (%) 51 49
Splenomegaly (%) 20 32
BMI* 25 ± 4 25 ± 4
ALT (IU/L)* 108 ± 65 96 ± 68
AST (IU/L)* 83 ± 36 85 ± 64
GGT (IU/L)* 88 ± 71 84 ± 52
Alkaline phosphatase (IU/L)* 72 ± 28 70 ± 27
Prothrombin time (%)* 82 ± 13 77 ± 16
Bilirubin (mg/dL)* 0.93 ± 0.35 0.99 ± 0.53
Albumin (g/dL)* 3.9 ± 0.5 3.9 ± 0.5
Child-Pugh score: A (%) 95 87
B (%)  5 13
Platelets (109/L)* 142 ± 48 124 ± 49
AFP (µg/L)* 15 ± 27 25 ± 42
Anti-HBc + (%) 32 30
Genotype 1b (%) 48 48
Knodell score* 10 ± 2.5 10 ± 2.2
* Mean ± SD.
In patients with known risk factors.
Abbreviations: IVDU, iv drug use; BMI, body/mass index; AST, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase; AFP, -fetoprotein; HBc, hepatitis B core.

Return To Article
  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 27 Aug 2008